Shire

Halozyme names Laurie Stelzer CFO

Monday, June 8, 2015

Halozyme Therapeutics, an oncology biotech company headquartered in San Diego, has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume chief financial officer  duties on June 15 and will work with Ramsay through a transition period.

[Read More]

Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

Monday, May 4, 2015

Shire and the Foundation Fighting Blindness, a national nonprofit organization focused on the entire spectrum of retinal diseases, have formed a new agreement to further research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There currently are no approved treatment options for adRP.

[Read More]

FDA grants Priority Review to lifitegrast NDA for dry eye disease in adults

Thursday, April 9, 2015

The FDA has accepted for filing Shire‘s NDA for lifitegrast and granted a Priority Review designation. Lifitegrast is an investigational treatment for dry eye disease in adults and, if approved, has the potential to be the first treatment indicated to address both signs and symptoms of the disease. The FDA is expected to provide a decision on October 25, based on the Prescription Drug User Fee Act V action date.

[Read More]

Pharming appoints Dr. Perry Calias chief scientific officer

Thursday, February 19, 2015

Pharming Group has appointed Dr. Perry Calias chief scientific officer. Calias will have overall responsibility for the company’s new enzyme replacement therapy (ERT) programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.

[Read More]

Vyvanse is FDA-approved for moderate to severe binge eating disorder

Thursday, February 5, 2015

The FDA has approved Shire’s Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (BED) in adults, shown to significantly reduce the mean number of binge days per week. Vyvanse is not indicated or recommended for weight loss or the treatment of obesity. Other sympathomimetic drugs used for weight loss have been associated with serious cardiovascular reactions.

[Read More]